Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 1
1995 2
1996 4
1997 6
1998 2
1999 1
2000 3
2001 7
2002 6
2003 7
2004 8
2005 7
2006 5
2007 8
2008 7
2009 9
2010 10
2011 11
2012 13
2013 14
2014 12
2015 19
2016 19
2017 25
2018 28
2019 27
2020 28
2021 30
2022 25
Text availability
Article attribute
Article type
Publication date

Search Results

316 results
Results by year
Filters applied: . Clear all
Page 1
Advances in immunotherapy for hepatocellular carcinoma.
Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Sangro B, et al. Among authors: melero i. Nat Rev Gastroenterol Hepatol. 2021 Aug;18(8):525-543. doi: 10.1038/s41575-021-00438-0. Epub 2021 Apr 13. Nat Rev Gastroenterol Hepatol. 2021. PMID: 33850328 Free PMC article. Review.
Dendritic cells in cancer immunology and immunotherapy.
Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D. Wculek SK, et al. Among authors: melero i. Nat Rev Immunol. 2020 Jan;20(1):7-24. doi: 10.1038/s41577-019-0210-z. Epub 2019 Aug 29. Nat Rev Immunol. 2020. PMID: 31467405 Review.
Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3.
Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, Chen L, Chen Y, Zhu G, Yin W, Zheng L, Zhou T, Badri T, Yao S, Zhu S, Boto A, Sznol M, Melero I, Vignali DAA, Schalper K, Chen L. Wang J, et al. Among authors: melero i. Cell. 2019 Jan 10;176(1-2):334-347.e12. doi: 10.1016/j.cell.2018.11.010. Epub 2018 Dec 20. Cell. 2019. PMID: 30580966 Free PMC article.
Paradigms on Immunotherapy Combinations with Chemotherapy.
Salas-Benito D, Pérez-Gracia JL, Ponz-Sarvisé M, Rodriguez-Ruiz ME, Martínez-Forero I, Castañón E, López-Picazo JM, Sanmamed MF, Melero I. Salas-Benito D, et al. Among authors: melero i. Cancer Discov. 2021 Jun;11(6):1353-1367. doi: 10.1158/2159-8290.CD-20-1312. Epub 2021 Mar 12. Cancer Discov. 2021. PMID: 33712487 Review.
Cytokines in clinical cancer immunotherapy.
Berraondo P, Sanmamed MF, Ochoa MC, Etxeberria I, Aznar MA, Pérez-Gracia JL, Rodríguez-Ruiz ME, Ponz-Sarvise M, Castañón E, Melero I. Berraondo P, et al. Among authors: melero i. Br J Cancer. 2019 Jan;120(1):6-15. doi: 10.1038/s41416-018-0328-y. Epub 2018 Nov 9. Br J Cancer. 2019. PMID: 30413827 Free PMC article. Review.
Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes.
Doroshow DB, Sanmamed MF, Hastings K, Politi K, Rimm DL, Chen L, Melero I, Schalper KA, Herbst RS. Doroshow DB, et al. Among authors: melero i. Clin Cancer Res. 2019 Aug 1;25(15):4592-4602. doi: 10.1158/1078-0432.CCR-18-1538. Epub 2019 Mar 1. Clin Cancer Res. 2019. PMID: 30824587 Free PMC article. Review.
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial.
Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B. Yau T, et al. Among authors: melero i. Lancet Oncol. 2022 Jan;23(1):77-90. doi: 10.1016/S1470-2045(21)00604-5. Epub 2021 Dec 13. Lancet Oncol. 2022. PMID: 34914889 Clinical Trial.
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, Ruth He A, El-Rayes BF, Acosta-Rivera M, Lim HY, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C. Yau T, et al. Among authors: melero i. JAMA Oncol. 2020 Nov 1;6(11):e204564. doi: 10.1001/jamaoncol.2020.4564. Epub 2020 Nov 12. JAMA Oncol. 2020. PMID: 33001135 Free PMC article. Clinical Trial.
316 results